Skip to main content

Peer Review reports

From: A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Original Submission
14 Oct 2024 Submitted Original manuscript
26 Dec 2024 Reviewed Reviewer Report
27 Dec 2024 Reviewed Reviewer Report
12 Feb 2025 Author responded Author comments - Dingwei Ye
21 Feb 2025 Reviewed Reviewer Report
5 Mar 2025 Reviewed Reviewer Report
7 Apr 2025 Author responded Author comments - Dingwei Ye
Resubmission - Version 2
12 Feb 2025 Submitted Manuscript version 2
Publishing
8 Apr 2025 Editorially accepted
9 May 2025 Article published 10.1186/s12916-025-04053-7

You can find further information about peer review here.

Back to article page